6
Participants
Start Date
October 31, 1997
Primary Completion Date
April 30, 2004
Study Completion Date
April 30, 2008
Daclizumab
Humanized anti-CD25 antibodies (anti-TAC), or placebo (saline solution), will be given as intravenous infusions on the following schedule: 2 mg/kg initially (maximum dose 200 mg) infusion given over 60 minutes, followed by a 1 mg/kg (maximum of 100 mg) infusion given over 30 minutes every two weeks thereafter for a total of 8 doses.
NB-UVB
total body NB-UVB at a dose that is 50% of the MED. Patients are treated 3-7 times per week, with increasing doses at every treatment if no burning occurs. This is continued until for a total of 20 ± 2 treatments total.
Rockefeller University Hospital, New York
Rockefeller University, New York
Rockefeller University, New York
Collaborators (1)
Facet Biotech
INDUSTRY
Rockefeller University
OTHER